Research Article
The Prognostic Role of SIRT1-Autophagy Axis in Gastric Cancer
Table 1
Association of Beclin-1, SIRT1, and their combined expression status with clinicopathological characteristics in GC.
| | Characteristics | N | Beclin-1 expression | SIRT1 expression | Beclin-1/SIRT1 expression | | High (%) | p | High (%) | p | Low/low
(%) | Low/high
(%) | High/low
(%) | High/high
(%) | p |
| | Gender | | | | | | | | | | | | Female | 21 | 13 (61.9) | 0.789 | 11 (52.4) | 0.768 | 8 (38.1) | 0 (0.0) | 2 (9.5) | 11 (52.4) | 0.341 | | Male | 75 | 44 (58.7) | 42 (56.0) | 22 (29.3) | 9 (12.0) | 11 (14.7) | 33 (44.0) | | Age (y) | | | | | | | | | | | | 60 | 45 | 24 (53.3) | 0.258 | 20 (44.4) | | 19 (42.2) | 2 (4.4) | 6 (13.3) | 18 (40.0) | 0.110 | | ≥60 | 51 | 33 (64.7) | 33 (64.7) | 11 (21.6) | 7 (13.7) | 7 (13.7) | 26 (51.0) | | BMI | | | | | | | | | | | | 24 | 75 | 43 (57.3) | 0.441 | 39 (52.0) | 0.232 | 25 (33.3) | 7 (9.3) | 11 (14.7) | 32 (42.7) | 0.680 | | ≥24 | 21 | 14 (66.7) | 14 (66.7) | 5 (23.8) | 2 (9.5) | 2 (9.5) | 12 (57.1) | | Tumor size (cm) | | | | | | | | | | | | 5 | 66 | 32 (48.5) | | 31 (47.0) | | 25 (37.9) | 9 (13.6) | 10 (15.2) | 22 (33.3) | | | 5 | 30 | 25 (83.3) | 22 (73.3) | 5 (16.7) | 0 (0.0) | 3 (10.0) | 22 (73.3) | | Tumor location | | | | | | | | | | | | Up | 36 | 23 (63.9) | 0.248 | 17 (47.2) | 0.232 | 12 (33.3) | 1 (2.8) | 7 (19.4) | 16 (44.4) | 0.222 | | Middle | 15 | 6 (40.0) | 7 (46.7) | 6 (40.0) | 3 (20.0) | 2 (13.3) | 4 (26.7) | | Lower | 45 | 28 (62.2) | 29 (64.4) | 12 (26.7) | 5 (11.1) | 4 (8.9) | 24 (53.3) | | Lauren classification | | | | | | | | | | | | Intestinal | 60 | 32 (53.3) | 0.120 | 31 (51.7) | 0.368 | 22 (36.7) | 6 (10.0) | 7 (11.7) | 25 (41.7) | 0.441 | | Diffuse | 36 | 25 (69.4) | 22 (61.1) | 8 (22.2) | 3 (8.3) | 6 (16.7) | 19 (52.8) | | Histologic grade | | | | | | | | | | | | WD and MD | 27 | 8 (39.6) | < | 9 (33.3) | | 16 (59.3) | 3 (11.1) | 2 (7.4) | 6 (22.2) | | | PD | 69 | 49 (71.0) | 44 (63.8) | 14 (20.3) | 6 (8.7) | 11 (15.9) | 38 (55.1) | | LN metastasis | | | | | | | | | | | | Absence | 24 | 3 (12.5) | < | 3 (12.5) | < | 19 (79.2) | 2 (8.3) | 2 (8.3) | 1 (4.2) | < | | Presence | 72 | 54 (75.0) | 50 (69.4) | 11 (15.3) | 7 (9.7) | 11 (15.3) | 43 (59.7) | | Tumor invasion | | | | | | | | | | | | EGC | 9 | 4 (44.4) | 0.547 | 1 (11.1) | | 5 (55.6) | 0 (0.0) | 3 (33.3) | 1 (11.1) | | | AGC | 87 | 53 (60.9) | 52 (59.8) | 25 (28.7) | 9 (10.3) | 10 (11.5) | 43 (49.4) | | TNM stage | | | | | | | | | | | | I and II | 23 | 3 (13.0) | < | 4 (17.4) | < | 17 (73.9) | 3 (13.0) | 2 (8.7) | 1 (4.3) | < | | III and IV | 73 | 54 (74.0) | 49 (67.1) | 13 (17.8) | 6 (8.2) | 11 (15.1) | 43 (58.9) | | VCE | | | | | | | | | | | | Absence | 57 | 28 (49.1) | | 28 (49.1) | 0.147 | 24 (42.1) | 5 (8.8) | 5 (8.8) | 23 (40.4) | | | Presence | 39 | 29 (74.4) | 25 (64.1) | 6 (15.4) | 4 (10.3) | 8 (20.5) | 21 (53.8) | | SIRT1 expression | | | | | | | | | | | | Low | 43 | 13 (30.2) | < | | | | | | | | | High | 53 | 44 (83.0) | | | | | | | |
|
|
BMI, body mass index; LN metastasis, lymph node metastasis; TNM stage, tumor node metastasis stage; VCE, vascular cancer embolus; WD, well differentiation; MD, middle differentiation; PD, poor differentiation; EGC, early gastric cancer; AGC, advantage gastric cancer; N, number of patients; ; .
|
